BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

SARS-CoV-2 binding sites for cytotoxic T cells  TScan Therapeutics Inc. reported in medRxiv that memory CD8 + T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from...
BioCentury | Jul 3, 2020

FDA’s pediatric anti-infective guidance encourages efficacy extrapolation, adolescent inclusion in adult pivotal trials

FDA’s latest pediatric guidance outlines what’s needed to extrapolate efficacy of anti-infective drugs from adults to children, and sends a clear message that adult trials should include patients aged 12 and up whenever possible. Because...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | Jun 9, 2020
Product Development

Lilly’s Junshi-partnered program becomes China’s first COVID-19 mAb in clinic

As EMA nears a decision on Gilead’s remdesivir to treat COVID-19 and a pair of groups take steps towards making vaccines available in the U.K., a second mAb against SARS-CoV-2 has entered clinical testing. Eli...
BioCentury | Jun 2, 2020
Product Development

Phase I start marks first for anti-SARS-CoV-2 mAbs, first for AbCellera

A COVID-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I...
BioCentury | May 28, 2020

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover...
BioCentury | Mar 21, 2020
Product Development

Coronavirus protease structure guides optimization of inhibitor

By solving the crystal structure of a SARS-CoV-2 protease, a University of Luebeck team was able to optimize a previously developed inhibitor for greater potency against the virus. In a paper published in Science on...
BioCentury | Mar 9, 2020

GenFleet eyes proof of concept with $50M series B

Looking to start its first international and proof-of-concept trials, GenFleet raised more than $50 million in a series B round led by CDH and Shenzhen Capital group. The round saw participation by new investors South...
Items per page:
1 - 10 of 560